Literature DB >> 24768365

Therapeutic application of contrast-enhanced ultrasound and low-dose urokinase for thrombolysis in a porcine model of acute peripheral arterial occlusion.

Harm P Ebben1, Johanna H Nederhoed2, Jeroen Slikkerveer3, Otto Kamp3, Geert W J M Tangelder4, René J P Musters4, Willem Wisselink2, Kak K Yeung5.   

Abstract

BACKGROUND: The addition of local ultrasound (US) with a contrast agent to standard intra-arterial thrombolysis can accelerate the thrombolytic treatment of stroke and myocardial infarction. The contrast agent consists of microsized gas-filled bubbles that collapse when exposed to US, causing destabilization of the clot and making the clot surface more susceptible to fibrinolytics. In this study, we investigated the effect of additional US and microbubbles on standard low-dose intra-arterial thrombolysis in a porcine model of extensive peripheral arterial occlusion.
METHODS: Extensive arterial thrombosis was induced in 10 pigs in the 4-cm external iliac artery by clamping and injection of 100 IU of bovine thrombin. A transcutaneous laser Doppler flow probe and an ultrasonic perivascular flow probe assessed microcirculation and arterial flow respectively. The urokinase-only (UK) group (n = 4) received standard thrombolytic therapy: intra-arterial bolus injection of 500,000 IU, followed by a continuous low-dose urokinase (50,000 IU/h) infusion through an intra-arterial catheter and local intermittent application of US, 1 second on, 5 seconds off, to visualize vascular patency during the first hour of therapy and to ensure microbubbles replenished the proximal portion of the occluded artery. The urokinase plus microbubbles (UK+) group (n = 6) received the same urokinase therapy with a concomitant intravenous infusion of microbubbles and local intermittent application of US. The contrast infusion protocol consisted of a bolus of two vials of 5 mL in the first 15 minutes and then three times 5 mL slowly hand-injected continuously during the next 45 min. After 3 hours of therapy, the animals were euthanized, and thrombi were harvested and weighed. All organs were cut in thin slices and macroscopically inspected for potential (hemorrhagic) adverse events, and tissue samples were taken.
RESULTS: Median thrombus weights were 1.1 g (range, 0.8-1.3 g) in the UK+ group vs 1.6 g (range, 1.3-1.9 g) in the UK group (P = .01). Arterial blood flow increased in four of six pigs in the UK+ group by a mean 61% vs in one of four in the UK group, with 1%. Microcirculation and lower limb arterial pressure levels improved after the start of therapy in the UK+ group, contrary to a trend of decline in the UK group. No signs of bleeding complications were observed in either group.
CONCLUSIONS: In this experimental pilot study, the addition of contrast-enhanced US accelerated the thrombolytic effect of low-dose intra-arterial thrombolysis in peripheral arterial occlusions. Further clinical studies are warranted.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24768365     DOI: 10.1016/j.jvs.2014.02.057

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  Thrombolysis in peripheral artery disease.

Authors:  Sotirios Giannakakis; George Galyfos; Ioannis Sachmpazidis; Kostas Kapasas; Stavros Kerasidis; Ioannis Stamatatos; Georgios Geropapas; Georgios Kastrisios; Gerasimos Papacharalampous; Chrisostomos Maltezos
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-02-05

Review 2.  Contrast Ultrasound, Sonothrombolysis and Sonoperfusion in Cardiovascular Disease: Shifting to Theragnostic Clinical Trials.

Authors:  Soufiane El Kadi; Thomas R Porter; Niels J W Verouden; Albert C van Rossum; Otto Kamp
Journal:  JACC Cardiovasc Imaging       Date:  2021-10-13

3.  Optical clearing imaging assisted evaluation of urokinase thrombolytic therapy on cerebral vessels with different sizes.

Authors:  Dongyu Li; Lu Deng; Zhengwu Hu; Yusha Li; Tingting Yu; Xiang Zhong; Jingtan Zhu; Dan Zhu
Journal:  Biomed Opt Express       Date:  2022-05-06       Impact factor: 3.562

4.  In vivo tissue optical clearing assisted through-skull targeted photothrombotic ischemic stroke model in mice.

Authors:  Zhengwu Hu; Dongyu Li; Xiang Zhong; Yusha Li; Ang Xuan; Tingting Yu; Jingtan Zhu; Dan Zhu
Journal:  J Biomed Opt       Date:  2022-06       Impact factor: 3.758

5.  Microbubbles and UltraSound-accelerated Thrombolysis (MUST) for peripheral arterial occlusions: protocol for a phase II single-arm trial.

Authors:  Harm P Ebben; Johanna H Nederhoed; Rutger J Lely; Willem Wisselink; Kakkhee Yeung
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

6.  Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA.

Authors:  Jianhui Wu; Haimei Zhu; Guodong Yang; Jianhong He; Yuji Wang; Shurui Zhao; Xiaoyi Zhang; Lin Gui; Ming Zhao; Shiqi Peng
Journal:  Int J Nanomedicine       Date:  2018-02-26

7.  A thrombolytic therapy using diagnostic ultrasound combined with RGDS-targeted microbubbles and urokinase in a rabbit model.

Authors:  Lina Guan; Chunmei Wang; Xue Yan; Liyun Liu; Yanhong Li; Yuming Mu
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

8.  In vivo evaluation of urokinase-loaded hollow nanogels for sonothrombolysis on suture embolization-induced acute ischemic stroke rat model.

Authors:  Yuming Teng; Haiqiang Jin; Ding Nan; Mengnan Li; Chenghe Fan; Yuanyuan Liu; Pu Lv; Wei Cui; Yongan Sun; Hongjun Hao; Xiaozhong Qu; Zhenzhong Yang; Yining Huang
Journal:  Bioact Mater       Date:  2017-08-24

Review 9.  Therapeutic application of contrast ultrasound in ST elevation myocardial infarction: Role in coronary thrombosis and microvascular obstruction.

Authors:  Jeroen Slikkerveer; Lynda Jm Juffermans; Niels van Royen; Yolande Appelman; Thomas R Porter; Otto Kamp
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2017-09-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.